SHALBY Shalby Q4 FY26 results (Jan–Mar 2026) and concall
Shalby Limited reported a strong Q4 FY26, with consolidated revenue growing 9.4% YoY and EBITDA surging 43.1%, driven by operational improvements and a favorable tax regime. The MedTech segment achieved a significant turnaround with positive EBITDA. While the international business faced headwinds from geopolitical issues, the company remains confident in its future growth, supported by strategic investments in oncology and robotics, and an improving doctor stability.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 8.3%, net profit up 250.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 268 | 276 | 265 | 296 | 285 +6% | 272 −1% | 287 +8% |
| EBITDA | 33 | 34 | 21 | 42 | 42 +27% | 30 −12% | 29 +38% |
| Net profit | 2 | -3 | -12 | 8 | 7 +250% | 1 +133% | 18 +250% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
